Gabather AB (publ) - Asset Resilience Ratio
Gabather AB (publ) (GABA) has an Asset Resilience Ratio of 66.54% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Gabather AB (publ) (GABA) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Gabather AB (publ)'s Asset Resilience Ratio has changed over time. See shareholders equity of Gabather AB (publ) for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Gabather AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Gabather AB (publ) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr907.00K | 66.54% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr907.00K | 66.54% |
Asset Resilience Insights
- Very High Liquidity: Gabather AB (publ) maintains exceptional liquid asset reserves at 66.54% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Gabather AB (publ) Industry Peers by Asset Resilience Ratio
Compare Gabather AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910 |
Drug Manufacturers - Specialty & Generic | 11.95% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 16.92% |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999 |
Drug Manufacturers - Specialty & Generic | 5.22% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 2.69% |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332 |
Drug Manufacturers - Specialty & Generic | 6.02% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Hainan Honz Pharmaceutical Co
SHE:300086 |
Drug Manufacturers - Specialty & Generic | 0.27% |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111 |
Drug Manufacturers - Specialty & Generic | 7.85% |
Annual Asset Resilience Ratio for Gabather AB (publ) (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Gabather AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 47.90% | Skr878.00K ≈ $94.49K |
Skr1.83 Million ≈ $197.26K |
+32.76pp |
| 2023-12-31 | 15.14% | Skr1.11 Million ≈ $119.99K |
Skr7.36 Million ≈ $792.48K |
-77.75pp |
| 2022-12-31 | 92.89% | Skr6.27 Million ≈ $674.97K |
Skr6.75 Million ≈ $726.62K |
-3.57pp |
| 2021-12-31 | 96.46% | Skr14.85 Million ≈ $1.60 Million |
Skr15.39 Million ≈ $1.66 Million |
+0.32pp |
| 2020-12-31 | 96.14% | Skr30.92 Million ≈ $3.33 Million |
Skr32.16 Million ≈ $3.46 Million |
-1.32pp |
| 2019-12-31 | 97.46% | Skr44.90 Million ≈ $4.83 Million |
Skr46.07 Million ≈ $4.96 Million |
+5.79pp |
| 2018-12-31 | 91.67% | Skr16.65 Million ≈ $1.79 Million |
Skr18.16 Million ≈ $1.95 Million |
+15.40pp |
| 2017-12-31 | 76.27% | Skr36.74 Million ≈ $3.95 Million |
Skr48.18 Million ≈ $5.18 Million |
-4.14pp |
| 2016-12-31 | 80.41% | Skr27.94 Million ≈ $3.01 Million |
Skr34.75 Million ≈ $3.74 Million |
-- |
About Gabather AB (publ)
Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. The company offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer's disease. It focuses on developing GT-002, a pro-cognitive drug candidate for the treatment … Read more